ENDRA Life Sciences Beheer

Beheer criteriumcontroles 2/4

De CEO ENDRA Life Sciences is Alex Tokman, benoemd in Aug2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.001% van de aandelen van het bedrijf, ter waarde $ 41.15. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.3 jaar en 9.3 jaar.

Belangrijke informatie

Alex Tokman

Algemeen directeur

US$103.3k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.0009%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	9.3yrs

Recente managementupdates

Recent updates

ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks

Sep 29

We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

Jul 19

ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer

Jun 15

ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology

Jan 13

ENDRA Life Sciences renews GE Healthcare collaboration agreement

Dec 21

Endra Life prices $5M-share offering

Dec 16

Endra Life Sciences EPS beats by $0.02

Nov 16

CEO

Alex Tokman (62 yo)

less than a year

Tenure

US$103,347

Compensatie

Mr. Alexander Y. Tokman, also known as Alex, serves as an Acting CEO and Director at ENDRA Life Sciences Inc. from August, 2024 also its Chairman. He serves as Independent Director at Izotropic Corporation...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alexander Tokman	Acting CEO & Chairman	less than a year	US$103.35k	0.00088% $ 41.1
Michael Thornton	Chief Technology Officer	17.8yrs	US$531.98k	0.0037% $ 171.6
Jonathan Behr	Co-Founder	no data	geen gegevens	geen gegevens
Richard Jacroux	CFO & Secretary	less than a year	geen gegevens	geen gegevens
Steve Freeman	Human Resources Leader	7.5yrs	geen gegevens	geen gegevens
Ziad Rouag	Head of Regulatory & Clinical Affairs	less than a year	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NDRA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Alexander Tokman	Acting CEO & Chairman	16.8yrs	US$103.35k	0.00088% $ 41.1
Anthony DiGiandomenico	Independent Director	11.8yrs	US$75.75k	0.011% $ 515.3
Michael Harsh	Independent Director	9.3yrs	US$73.57k	0.00038% $ 17.8
Louis Basenese	Independent Director	4.6yrs	US$65.07k	0.00027% $ 12.6
Jonathan Rubin	Scientific Advisor	9.3yrs	geen gegevens	geen gegevens
Jing Gao	Scientific Advisor	no data	geen gegevens	geen gegevens
Raza Malik	Scientific Advisor	4.8yrs	geen gegevens	geen gegevens

9.3yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NDRA wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).

ENDRA Life Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ENDRA Life Sciences Inc. Announces Chief Executive Officer Changes

ENDRA Life Sciences Inc., Annual General Meeting, Aug 06, 2024

ENDRA Life Sciences Inc., Annual General Meeting, Aug 09, 2023

ENDRA Life Sciences Inc., Annual General Meeting, Jul 06, 2023

Insufficient new directors

ENDRA Life Sciences Inc. Announces Resignation of Renaud Maloberti as Chief Commercial Officer, Effective January 13, 2023

Recent updates

Nasdaq Hearings Panel Grants ENDRA Life Sciences an Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

New major risk - Financial position

ENDRA Life Sciences Inc. Announces Chief Executive Officer Changes

ENDRA Life Sciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

ENDRA Life Sciences Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

ENDRA Life Sciences Inc., Annual General Meeting, Aug 06, 2024

Consensus revenue estimates decrease by 50%, EPS upgraded

New major risk - Shareholder dilution

Endra Life Sciences Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024

ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024

ENDRA Life Sciences Inc. to Report Q1, 2024 Results on May 14, 2024

Endra Life Sciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Revenue and earnings growth

ENDRA Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $6.2 million.

New major risk - Market cap size

ENDRA Life Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

ENDRA Life Sciences Inc. Welcomes the Adoption of the ICD-10 K76.0 Code for the Diagnosis of Non-Alcoholic Fatty Liver Disease

ENDRA Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $6.2 million.

New major risk - Market cap size

New major risk - Revenue and earnings growth

ENDRA Life Sciences Inc. to Report Q3, 2023 Results on Nov 14, 2023

ENDRA Life Sciences Submits De Novo Request for its TAEUS System Liver Fat Application to the U.S. FDA

ENDRA Life Sciences Inc. to Report First Half, 2023 Results on Aug 14, 2023

ENDRA Life Sciences Inc., Annual General Meeting, Aug 09, 2023

New major risk - Market cap size

Consensus revenue estimates decrease by 90%, EPS upgraded

ENDRA Life Sciences Inc., Annual General Meeting, Jul 06, 2023

ENDRA Life Sciences Inc. to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Consensus revenue estimates increase by 57%, EPS downgraded

ENDRA Life Sciences Inc. Announces Resignation of Renaud Maloberti as Chief Commercial Officer, Effective January 13, 2023

Consensus forecasts updated

ENDRA Life Sciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

ENDRA Life Sciences Inc. Plans to Submit De Novo Request to U.S. FDA for Its TAEUS System

ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks

Consensus revenue estimates fall by 39%

Price target decreased to US$4.75

ENDRA Life Sciences receives European patent for TAEUS system

Endra Life Sciences Q2 2022 Earnings Preview

We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

ENDRA Life Sciences Inc. to Report Q2, 2022 Results on Aug 15, 2022

Consensus revenue estimates fall by 21%

Consensus forecasts updated

ENDRA Life Sciences Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$5.25

Consensus revenue estimates fall by 79%

Price target decreased to US$5.63

ENDRA Life Sciences Inc. Provides Update on U.S. Regulatory Strategy for its TAEUS® System

We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

Price target increased to US$6.50

Independent Director recently sold US$92k worth of stock

Price target increased to US$6.25

We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer

Consensus forecasts updated

ENDRA Life Sciences Inc. to Report Q4, 2020 Results on Mar 25, 2021

ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology

New 90-day high: US$0.92

ENDRA Life Sciences renews GE Healthcare collaboration agreement

ENDRA Life Sciences Inc. has completed a Follow-on Equity Offering in the amount of $5.0001 million.

Endra Life prices $5M-share offering

New 90-day high: US$0.90

ENDRA Life Sciences Announces New Clinical Study Partnership with the Centre Hospitalier Universitaire d'Angers, France

New 90-day high: US$0.85

Analysts update estimates

Endra Life Sciences EPS beats by $0.02

Price target raised to US$5.08

New 90-day low: US$0.70